Entering text into the input field will update the search result below

Sequenom Q4 and FY14 results

  • Sequenom (NASDAQ:SQNM +3.8%) Q4 results: Revenues: $36.8M (+12.5%); COGS: $17.3M (-22.4%); R&D Expense: $5.1M (-32.9%); SG&A: $17.3M (-21.0%); Operating Income: $20M (+204.2%); Net Income: $16.7M (+184.8%); EPS: $0.13 (+176.5%).
  • FY2014 results: Revenues: $151.6M (+26.8%); COGS: $83.5M (-4.4%); R&D Expense: $25M (-35.4%); SG&A: $77.7M (-13.8%); Operating Loss: ($13.7M) (+86.6%); Net Loss: ($14.5M) (+86.8%); Loss Per Share: ($0.12) (+87.4%); Quick Assets: $93.9M (+31.7%).
  • No guidance given.

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

05 Mar. 2015
Sequenom going into 2015 continues to move gross profit margin higher going from 38% to 53% which is very positive for the company. Revenues counting the patent pools could very well reach 200 million in 2015. Estimates don't include Visibiliti T or Heredi T. News of the Federal Court of Appeals case involving Roche (Ariosa) could occur as early as April. Does Roche become part of the patent pool prior to this? If not how severe would the damages be if Sequenom wins? Keep an eye on others licensing in the pool in 2015. Does Sequenom get insurance reimbursement in the 4th quarter on Visibiliti T? Does Sequenom bring Liquid Biopsy to market commercially in 2016? My opinion is that 2015 will be a positive year for Sequenom as far as stock appreciation is concerned but 2016 will show significant growth for this company with Visibiliti T.

Related Stocks

SymbolLast Price% Chg
Sequenom, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.